Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:38:32 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CORT - CORCEPT THERAPEUTICS INC - https://www.corcept.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CORT - Q0.138.40·50.000.840.83+2.476.41,384.555,03114,43639.01  40.846  38.68117.33  32.990619:59:38Jan 2215 min RT 2¢

Recent Trades - Last 10 of 14436
Time ETExPriceChangeVolume
19:59:38Q40.832.471
19:40:46Q40.802.442
18:18:05Q40.832.476
17:43:41Q40.832.4774,784
17:40:12Q40.802.4425
17:31:00Q40.812.4518
17:25:19Q40.812.459
17:25:19Q40.812.451
17:25:19Q40.802.441
17:18:26Q40.792.433

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-22 08:00U:CORTNews ReleaseOverall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
2025-12-31 08:00U:CORTNews ReleaseCorcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
2025-11-04 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
2025-10-28 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
2025-10-19 05:15U:CORTNews ReleaseCorcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
2025-10-14 08:00U:CORTNews ReleaseCorcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
2025-09-22 14:30U:CORTNews ReleaseCorcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
2025-09-10 08:00U:CORTNews ReleaseFDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
2025-07-31 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
2025-07-24 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
2025-07-14 08:00U:CORTNews ReleaseCorcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
2025-06-23 16:30U:CORTNews ReleaseCorcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
2025-06-05 06:00U:CORTNews ReleaseCorcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
2025-06-02 11:15U:CORTNews ReleaseCorcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
2025-05-05 16:05U:CORTNews ReleaseCORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
2025-04-28 16:05U:CORTNews ReleaseCORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
2025-04-23 11:30U:CORTNews ReleaseCORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
2025-04-21 08:00U:CORTNews ReleaseDiabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
2025-04-07 08:00U:CORTNews ReleaseCorcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
2025-03-31 08:00U:CORTNews ReleasePrimary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer